The litigation, Mazzarino v. ADMA Biologics, Inc., et al., alleges that the company and several executives violated federal securities laws by failing to disclose material information in official offering documents. The complaint asserts that the company engaged in undisclosed related party transactions and utilized channel stuffing to artificially inflate revenue figures. Furthermore, the suit claims the firm lacked adequate internal controls, rendering statements regarding its business operations and financial prospects misleading to shareholders.
In section Releases
Investors Face August 10 Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek appointment as lead plaintiff in a pending class action lawsuit filed in the United States District Court for the District of New Jersey.
Kahn Swick & Foti, LLC, the firm representing the plaintiffs, maintains that these omissions caused significant financial damages to investors once the details reached the market. Those who suffered losses during the specified period may contact managing partner Lewis Kahn at 1-877-515-1850 or via the firm's website to review their legal options. Participation in a potential recovery does not mandate serving as a lead plaintiff, though the August 10 deadline remains critical for those seeking a formal role in the court proceedings.
Comments (0)
No comments yet. Be the first!